Do analysts recommend SMWB or ZSQR?

Similarweb currently has a consensus target price of $9.71, indicating a potential upside of 23.14%. Given Similarweb's stronger consensus rating and higher possible upside, equities research analysts plainly believe Similarweb is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Similarweb 1 Sell rating(s) 5 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.36 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PAR or ZSQR?

PAR Technology presently has a consensus price target of $23.06, indicating a potential upside of 5.01%. Given PAR Technology's stronger consensus rating and higher possible upside, research analysts clearly believe PAR Technology is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAR Technology 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend DCBO or ZSQR?

Docebo presently has a consensus target price of $36.25, suggesting a potential upside of 11.15%. Given Docebo's stronger consensus rating and higher possible upside, research analysts plainly believe Docebo is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Docebo 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.79 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate YEXT or ZSQR?

Yext presently has a consensus price target of $6.33, suggesting a potential downside of 17.05%. Given Yext's stronger consensus rating and higher possible upside, research analysts clearly believe Yext is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yext 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is YEXT or ZSQR more profitable?

Yext has a net margin of 5.90% compared to Coeptis Therapeutics' net margin of -773.72%. Yext's return on equity of 43.23% beat Coeptis Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Yext 5.90% 43.23% 7.50% Coeptis Therapeutics -773.72% -49.45% -46.88%

Do analysts rate ZSQR or SPT?

Sprout Social has a consensus price target of $12.17, indicating a potential upside of 6.21%. Given Sprout Social's stronger consensus rating and higher possible upside, analysts clearly believe Sprout Social is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sprout Social 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.36

Coeptis Therapeutics (ZSQR) Competitors

$2.38 -0.09 (-3.64%)

As of 12:02 PM Eastern

Compare

ZSQR vs. SMWB, PAR, DCBO, YEXT, and SPT

Should you buy Coeptis Therapeutics stock or one of its competitors? Coeptis Therapeutics's main competitors and comparable companies include Similarweb (SMWB), PAR Technology (PAR), Docebo (DCBO), Yext (YEXT), and Sprout Social (SPT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Coeptis Therapeutics compare to Similarweb?

Similarweb (NYSE:SMWB) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

57.6% of Similarweb shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 62.4% of Similarweb shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Similarweb has a net margin of -7.37% compared to Coeptis Therapeutics' net margin of -773.72%. Similarweb's return on equity of -19.81% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Similarweb	-7.37%	-19.81%	-1.74%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

In the previous week, Similarweb had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Similarweb and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.82 beat Similarweb's score of 0.82 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Similarweb	Positive
Coeptis Therapeutics	Very Positive

Similarweb has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market.

Similarweb currently has a consensus target price of $9.71, indicating a potential upside of 23.14%. Given Similarweb's stronger consensus rating and higher possible upside, equities research analysts plainly believe Similarweb is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Similarweb	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Coeptis Therapeutics has lower revenue, but higher earnings than Similarweb. Similarweb is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Similarweb	$282.60M	2.45	-$32.94M	-$0.25	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

Summary

Similarweb beats Coeptis Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to PAR Technology?

PAR Technology (NYSE:PAR) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

13.9% of Coeptis Therapeutics shares are held by institutional investors. 2.3% of PAR Technology shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PAR Technology presently has a consensus price target of $23.06, indicating a potential upside of 5.01%. Given PAR Technology's stronger consensus rating and higher possible upside, research analysts clearly believe PAR Technology is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAR Technology	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PAR Technology has a net margin of -12.24% compared to Coeptis Therapeutics' net margin of -773.72%. PAR Technology's return on equity of -0.69% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAR Technology	-12.24%	-0.69%	-0.41%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

In the previous week, PAR Technology had 18 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 19 mentions for PAR Technology and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.82 beat PAR Technology's score of 0.52 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PAR Technology	Positive
Coeptis Therapeutics	Very Positive

Coeptis Therapeutics has lower revenue, but higher earnings than PAR Technology. PAR Technology is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAR Technology	$455.55M	1.99	-$84.46M	-$1.53	N/A
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

PAR Technology has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market.

Summary

PAR Technology beats Coeptis Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Docebo?

Docebo (NASDAQ:DCBO) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Docebo presently has a consensus target price of $36.25, suggesting a potential upside of 11.15%. Given Docebo's stronger consensus rating and higher possible upside, research analysts plainly believe Docebo is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Docebo	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

53.2% of Docebo shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Docebo has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market.

In the previous week, Docebo had 26 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 27 mentions for Docebo and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.82 beat Docebo's score of 0.71 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Docebo	Positive
Coeptis Therapeutics	Very Positive

Docebo has a net margin of 13.79% compared to Coeptis Therapeutics' net margin of -773.72%. Docebo's return on equity of 233.03% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Docebo	13.79%	233.03%	16.65%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Docebo has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Docebo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Docebo	$242.69M	3.36	$37.51M	$1.30	25.09
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

Summary

Docebo beats Coeptis Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Yext?

Yext (NYSE:YEXT) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Yext presently has a consensus price target of $6.33, suggesting a potential downside of 17.05%. Given Yext's stronger consensus rating and higher possible upside, research analysts clearly believe Yext is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yext	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Coeptis Therapeutics had 1 more articles in the media than Yext. MarketBeat recorded 1 mentions for Coeptis Therapeutics and 0 mentions for Yext. Coeptis Therapeutics' average media sentiment score of 1.82 beat Yext's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Yext	Neutral
Coeptis Therapeutics	Very Positive

Yext has a net margin of 5.90% compared to Coeptis Therapeutics' net margin of -773.72%. Yext's return on equity of 43.23% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yext	5.90%	43.23%	7.50%
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%

Yext has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market.

Yext has higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Yext, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yext	$446.58M	1.69	$37.87M	$0.17	44.91
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A

71.0% of Yext shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 7.8% of Yext shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Yext beats Coeptis Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Coeptis Therapeutics compare to Sprout Social?

Coeptis Therapeutics (NASDAQ:ZSQR) and Sprout Social (NASDAQ:SPT) are both small-cap technology companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Coeptis Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market. Comparatively, Sprout Social has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

In the previous week, Sprout Social had 17 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 18 mentions for Sprout Social and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 1.82 beat Sprout Social's score of 0.69 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coeptis Therapeutics	Very Positive
Sprout Social	Positive

Sprout Social has a net margin of -5.42% compared to Coeptis Therapeutics' net margin of -773.72%. Sprout Social's return on equity of 1.11% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-773.72%	-49.45%	-46.88%
Sprout Social	-5.42%	1.11%	0.46%

Coeptis Therapeutics has higher earnings, but lower revenue than Sprout Social. Sprout Social is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$1.63	N/A
Sprout Social	$457.55M	1.52	-$43.33M	-$0.45	N/A

Sprout Social has a consensus price target of $12.17, indicating a potential upside of 6.21%. Given Sprout Social's stronger consensus rating and higher possible upside, analysts clearly believe Sprout Social is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sprout Social	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

13.9% of Coeptis Therapeutics shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Sprout Social shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Sprout Social beats Coeptis Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Coeptis Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZSQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZSQR vs. The Competition

Export

Metric	Coeptis Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$126.14M	$15.71B	$26.72B	$12.01B
Dividend Yield	N/A	3.38%	2.89%	4.50%
P/E Ratio	-1.46	48.26	44.46	30.36
Price / Sales	N/A	6.13	5.64	5.82
Price / Cash	N/A	28.09	27.75	22.80
Price / Book	0.90	6.24	5.31	3.77
Net Income	-$11.92M	$424.69M	$786.79M	$390.55M
7 Day Performance	-29.17%	-0.42%	0.95%	-0.58%
1 Month Performance	-53.88%	-4.32%	-8.17%	-6.84%
1 Year Performance	-83.18%	-10.54%	1.91%	-6.12%

Coeptis Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZSQR Coeptis Therapeutics	0.5954 of 5 stars	$2.38 -3.6%	N/A	-83.0%	$126.14M	N/A	N/A	6	Positive News
SMWB Similarweb	3.5672 of 5 stars	$8.80 +0.5%	$9.71 +10.5%	+1.6%	$766.51M	$282.60M	N/A	1,000	Upcoming Earnings Analyst Forecast
PAR PAR Technology	1.2841 of 5 stars	$18.95 +4.5%	$24.61 +29.9%	-44.6%	$749.91M	$455.55M	N/A	1,809	Analyst Forecast High Trading Volume
DCBO Docebo	3.498 of 5 stars	$30.89 +3.1%	$31.30 +1.3%	+37.9%	$748.03M	$242.69M	27.10	966	Earnings Report Dividend Announcement Analyst Forecast
YEXT Yext	0.7463 of 5 stars	$7.86 +4.7%	$6.33 -19.4%	-11.7%	$742.34M	$446.58M	46.21	1,120	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZSQR) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. SMWB, PAR, DCBO, YEXT, and SPT

How does Coeptis Therapeutics compare to Similarweb?

Summary

How does Coeptis Therapeutics compare to PAR Technology?

Summary

How does Coeptis Therapeutics compare to Docebo?

Summary

How does Coeptis Therapeutics compare to Yext?

Summary

How does Coeptis Therapeutics compare to Sprout Social?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coeptis Therapeutics (ZSQR) Competitors

ZSQR vs. SMWB, PAR, DCBO, YEXT, and SPT

How does Coeptis Therapeutics compare to Similarweb?

Do institutionals and insiders have more ownership in SMWB or ZSQR?

Is SMWB or ZSQR more profitable?

Does the media prefer SMWB or ZSQR?

Which has more volatility and risk, SMWB or ZSQR?

Do analysts recommend SMWB or ZSQR?

Which has preferable valuation and earnings, SMWB or ZSQR?

Summary

How does Coeptis Therapeutics compare to PAR Technology?

Do institutionals & insiders have more ownership in PAR or ZSQR?

Do analysts recommend PAR or ZSQR?

Is PAR or ZSQR more profitable?

Does the media prefer PAR or ZSQR?

Which has stronger earnings & valuation, PAR or ZSQR?

Which has more risk & volatility, PAR or ZSQR?

Summary

How does Coeptis Therapeutics compare to Docebo?

Do analysts recommend DCBO or ZSQR?

Do insiders & institutionals hold more shares of DCBO or ZSQR?

Which has more volatility & risk, DCBO or ZSQR?

Does the media prefer DCBO or ZSQR?

Is DCBO or ZSQR more profitable?

Which has stronger valuation and earnings, DCBO or ZSQR?

Summary

How does Coeptis Therapeutics compare to Yext?

Do analysts rate YEXT or ZSQR?

Does the media prefer YEXT or ZSQR?

Is YEXT or ZSQR more profitable?

Which has more volatility & risk, YEXT or ZSQR?

Which has better valuation & earnings, YEXT or ZSQR?

Do institutionals and insiders hold more shares of YEXT or ZSQR?

Summary

How does Coeptis Therapeutics compare to Sprout Social?

Which has more volatility & risk, ZSQR or SPT?

Does the media refer more to ZSQR or SPT?

Is ZSQR or SPT more profitable?

Which has preferable valuation & earnings, ZSQR or SPT?

Do analysts rate ZSQR or SPT?

Do insiders and institutionals have more ownership in ZSQR or SPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZSQR vs. The Competition

Coeptis Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools